VICL stock forecast
Our latest prediction for Vical, Inc.'s stock price was made on the June 28, 2018 when the stock price was at 1.20$.
In the short term (2weeks), VICL's stock price should outperform the market by 6.04%. During that period the price should oscillate between -8.30% and +19.07%.
In the medium term (3months), VICL's stock price should outperform the market by 11.36%. During that period the price should oscillate between -18.55% and +54.95%.Get email alerts
About Vical, Inc.
Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA.
At the moment the company generates 5M USD in revenues.
On its last earning announcement, the company reported a loss of -0.77$ per share.
The book value per share is 2.46$
Three months stock forecastJune 28, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|